⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 15, 2024Journal of Epidemiology and Global HealthOpen Access

Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome

A. Torres Brima M. Younis Mohammed Alamin Samuel Tesema Lorena Bernardo José Carlos Solana Javier Moreno Ahmed Ali Khidir Mustafa Fabiana Alves Ahmed Musa Eugenia Carrillo

View Full Paper

Ask AI

Bookmark

Share

Abstract

The host cellular immune response associated with two treatments for post-kala-azar dermal leishmaniasis (PKDL) - paromomycin plus miltefosine (Arm 1), and liposomal amphotericin B plus miltefosine (Arm 2) - was examined in Sudanese patients before treatment (D0), at the end of treatment (D42), and during the post-treatment period (D180).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Torres et al. (2024) studied this question.

synapsesocial.com/papers/68e60368b6db6435875971fa https://doi.org/10.1007/s44197-024-00270-0

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh2024 · 19 citations
2Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis2024 · 6 citations
3Amphotericin B Deoxycholate Treatment of Post–Kala-Azar Dermal Leishmaniasis in India2024 · 2 citations
4Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasisOriginal Research · 2026 · 1 citations
5Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa2024 · 6 citations